Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Society Launches Consultations On Regulation Of Conduct In Schools Of Pharmacy
Students and staff, among others in the profession, have the chance to make their views
new payday loan lenders
Buy zoloft and forget about depression.
Blogs Comment On 'Common Ground' Bill, Abortion Coverage In Health Reform Legislation, Other Topics
The following summarizes selected women"s health-related blog entries.~ "Democratic Bill Could Be a Preview of Obama"s Abortion Plan," Dan Gilgoff, U.S. News & World Report"s "God and Country": A recently introduced bill aimed at reducing the need for abortion is "big news because moderate to liberal faith-based advocates are urging the White House to adopt the bill ... as the core of its forthcoming "common ground" plan on abortion and reproductive health," Gilgoff writes. Some conservative religious groups, including the Southern Baptist Convention and the U.S. Conference of Catholic Bishops, "have warned the White House" that the bill is a "deal breaker" for them because of its support for comprehensive sex education and contraception, he writes. The White House "has refused to say which way it"s leaning," Gilgoff writes, adding the Obama administration could "buck" the groups that support the bill and "get behind" the Pregnant Women Support Act, "which is generally considered more robust on reducing demand for abortions and which leaves out contraceptive funding." However, he concludes, "that would be a pretty big surprise" (Gilgoff, "God and Country," U.S. News & World Report, 7/23).~ "New Report: Abortion Providers = American Human Rights Defenders, Now Under Increasing Attack," Jodi Jacobson, RH Reality Check: A new Center for Reproductive Rights report "calls on both the federal and state governments to address the growing threats against and stigmatization and abuse of abortion providers throughout the United States," Jacobson writes. The report "focuses on a key obstacle to the realization of women"s reproductive rights ... and recognizes their work as human rights defenders," she writes, adding that the U.S. has "historically been a leader both in creating and in encouraging accountability to human rights principles throughout the world." However, "[a]ccess to reproductive health care generally and abortion care specifically are basic human rights largely ignored within the context of U.S. domestic politics," Jacobson writes, noting that abortion access in the U.S. "has been increasingly limited due to the range of obstacles created through anti-choice advocacy." The report highlights several "types of rights violations [that] are most pervasive in limiting women"s choices and the rights of abortion providers," including "intimidation and harassment," "stigma" and "legal restrictions." The report makes a "series of recommendations for change at the state and local level for changes in policy and in law enforcement practices, as well as for the federal government, medical community and non-governmental organizations," Jacobson concludes, adding that the report "makes a special plea for the United Nations Special Rapporteur to document violations of women"s human rights in the United States" (Jacobson, RH Reality Check, 7/22).~ "Sixteen Governors Call on Congress To Include Medicaid Family Planning State Option in Health Reform," Jodi Jacobson, RH Reality Check: "Sixteen governors have written a letter to both Senate and House Leadership "expressing strong support for the Medicaid Family Planning State Option,"" which is included in President Obama"s fiscal year 2010 budget proposal, Jacobson writes. The governors wrote, "Many of our states have created family planning expansion programs, though we have done so with great difficulty," adding, "Since the early 1990s, 27 states have been granted federal waivers to expand their Medicaid family planning coverage. These demonstration projects have been unqualified successes, providing care to millions of women while saving states [millions] of dollars." Jacobson continues, "The current Medicaid waiver process, however, "puts unnecessary roadblocks in the way of our efforts to maintain and expand coverage for family planning services,"" according to the governors. She adds, "Passing this law as part of health care reform "would give us the needed flexibility to quickly and efficiently expand cove
News of the day
Bad Mitochondria May Actually Be Good For You
Mice with a defective mitochondrial protein called MCLK1 produce elevated amounts of reactive oxygen when young; that should spell disaster, yet according to a study in this week"s JBC these mice actually age at a slower rate and live longer than normal mice.
Public Health

Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer

Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women"s Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company"s aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. About OSI Pharmaceuticals OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world"s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche"s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer"s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx"s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx"s Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law. This news release also contains forward-looking statements of OSI. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI"s and its collaborators" abilities to effectively market and sell Tarceva and to expand the approved indications for Tarceva, OSI"s ability to protect its intellectual property rights, safety concerns regarding Tarceva, competition to Tarceva and OSI"s drug candidates from other biotechnology and pharmaceutical companies, the completion of clinical trials, the effects of FDA and other governmental regulation, including pricing controls, OSI"s ability to successfully develop and commercialize drug candidates, and other factors described in OSI Pharmaceuticals" filings with the Securities and Exchange Commission References (1) El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750 (2) Available at American Society of Clinical Oncology: http://www.asco.org/patient/Cancer+Types/Liver+Cancer. (3) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004. (4) Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Bayer HealthCare Pharmaceuticals Inc

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009